Zogenix stock analysis involves checking at least a few of the important things like: Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that ZGNX stock
Zogenix Inc. (ZGNX) traded on unusually high volume on Aug. 09, as the stock lost 13.77% to close at $10.65. On the day, Zogenix Inc. saw 592,931 shares trade hands on 4,757 trades. Considering that the stock averages only a daily …
Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $26.00 target price on shares of Zogenix in a research note on Monday, June 26th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating …
Results of the second pivotal phase 3 study are expected in Q1 2018. We are initiating coverage on its common stock with Buy rating and initial price target of $30. Zogenix (NASDAQ:ZGNX) is an emerging biopharmaceutical company with …
They currently have a $28.00 PT on the company. Brean Capital’s target suggests a potential upside of 52.09% from the company’s last stock close price. NASDAQ:ZGNX is currently trading -2.02% lower at $18.41 as of 18:26 New York …
Zogenix, Inc. (NASDAQ:ZGNX)‘s stock had its “buy” rating reaffirmed by investment analysts at Stifel Nicolaus in a report released on Monday, June 26th. They presently have a $26.00 price objective on the stock. Stifel Nicolaus’ target price ...
RA Capital Management, led by Peter Kolchinsky, has disclosed a massive new stake in California-based pharmaceutical company Zogenix, Inc (NASDAQ:ZGNX). A new filing with the U.S. Securities and Exchange Commission revealed …
Unlike Zohydro from ZNGX, Purdue Pharma’s drug is more difficult to crush — making it harder for addicts to abuse the drug. Both drugs are powerful painkillers designed to treat chronic lower back pain. The potential for Zohydro abuse …
One stock that might be an intriguing choice for investors right now is Zogenix, Inc. ( ZGNX). This is because this security in the Medical Drug space is seeing solid earnings estimate revision activity, and is in great company from a Zacks …